---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196459"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:27:33.195631+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru Q3 net rev $4.0M, net loss $0.07; Phase 2b QUALITY study fully enrolled (>150 pts), topline Jan 2025

## Summary
- Q3 net revenue $4.0M (up 21% YoY); operating loss $10.9M vs $13.7M.
- Net loss $11.0M ($0.07/sh) vs $12.5M ($0.14/sh) prior year.
- Phase 2b QUALITY trial full enrollment >150 patients achieved; topline lean body mass data expected Jan 2025.
- Cash $29.2M at June 30, 2024 vs $9.6M at Sept 30, 2023.
- Enobosarm aims to preserve muscle during GLP-1 weight loss; extension study data expected Q2 2025.

## SEC filing metadata
- accession: 0001193125-24-196459
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312524196459/0001193125-24-196459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312524196459/d877606d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196459
- JSON: https://secwatch.observer/filing/0001193125-24-196459.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.